Vraylar

Overview

cariprazine

atypical antipsychotic

• CYP3A4 substrate
• CNS depression
• decreases central histamine effects
• extrapyramidal effects
• hyperglycemic effects
• hyperthermia
• hypotensive effects
• lowers seizure threshold

Avoid/Use Alternative

• adagrasib
Vraylar (cariprazine)

+

adagrasib

1 interaction

Avoid/Use Alternative

cariprazine + adagrasib

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING ADAGRASIB: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• aldesleukin
Vraylar (cariprazine)

+

aldesleukin

1 interaction

Avoid/Use Alternative

cariprazine + aldesleukin

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, severe or life-threatening hypotension (including orthostasis, syncope), seizures (additive effects)

• amifampridine
Vraylar (cariprazine)

+

amifampridine

1 interaction

Avoid/Use Alternative

cariprazine + amifampridine

consider alternative: combo may incr. risk of seizures (additive effects)

• apalutamide
Vraylar (cariprazine)

+

apalutamide

1 interaction

Avoid/Use Alternative

cariprazine + apalutamide

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• aprepitant
Vraylar (cariprazine)

+

aprepitant

1 interaction

Avoid/Use Alternative

cariprazine + aprepitant

aprepitant x1 dose OK; for aprepitant 3-day regimen: IF STARTING CARIPRAZINE: ADULTS: adjust dose as: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS: avoid combo; IF STABLE CARIPRAZINE AND STARTING APREPITANT: ADULT/PEDS, ALL USES: adjust cariprazine dose as: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• aripiprazole bimonthly injection
Vraylar (cariprazine)

+

aripiprazole bimonthly injection

1 interaction

Avoid/Use Alternative

cariprazine + aripiprazole bimonthly injection

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• aripiprazole lauroxil
Vraylar (cariprazine)

+

aripiprazole lauroxil

1 interaction

Avoid/Use Alternative

cariprazine + aripiprazole lauroxil

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• aripiprazole monthly injection
Vraylar (cariprazine)

+

aripiprazole monthly injection

1 interaction

Avoid/Use Alternative

cariprazine + aripiprazole monthly injection

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• aripiprazole oral
Vraylar (cariprazine)

+

aripiprazole oral

1 interaction

Avoid/Use Alternative

cariprazine + aripiprazole oral

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• asenapine
Vraylar (cariprazine)

+

asenapine

1 interaction

Avoid/Use Alternative

cariprazine + asenapine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• atazanavir
Vraylar (cariprazine)

+

atazanavir

1 interaction

Avoid/Use Alternative

cariprazine + atazanavir

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING ATAZANAVIR: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• avacopan
Vraylar (cariprazine)

+

avacopan

1 interaction

Avoid/Use Alternative

cariprazine + avacopan

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING AVACOPAN: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• benztropine
Vraylar (cariprazine)

+

benztropine

1 interaction

Avoid/Use Alternative

cariprazine + benztropine

consider alternative: combo may incr. risk of hyperthermia, including life-threatening (additive effects)

• berotralstat
Vraylar (cariprazine)

+

berotralstat

1 interaction

Avoid/Use Alternative

cariprazine + berotralstat

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING BEROTRALSTAT: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• bosentan
Vraylar (cariprazine)

+

bosentan

1 interaction

Avoid/Use Alternative

cariprazine + bosentan

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• butalbital
Vraylar (cariprazine)

+

butalbital

1 interaction

Avoid/Use Alternative

cariprazine + butalbital

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• carbamazepine
Vraylar (cariprazine)

+

carbamazepine

1 interaction

Avoid/Use Alternative

cariprazine + carbamazepine

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy; may alter seizure control; may incr. risk of CNS depression, psychomotor impairment, hypotension, including syncope (hepatic metabolism induced; antagonistic effects, cariprazine may decr. seizure threshold; additive effects)

• cenobamate
Vraylar (cariprazine)

+

cenobamate

1 interaction

Avoid/Use Alternative

cariprazine + cenobamate

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, cariprazine may decr. seizure threshold)

• ceritinib
Vraylar (cariprazine)

+

ceritinib

1 interaction

Avoid/Use Alternative

cariprazine + ceritinib

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING CERITINIB: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• chloramphenicol
Vraylar (cariprazine)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

cariprazine + chloramphenicol

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING CHLORAMPHENICOL: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• ciprofloxacin
Vraylar (cariprazine)

+

ciprofloxacin

1 interaction

Avoid/Use Alternative

cariprazine + ciprofloxacin

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING CIPROFLOXACIN: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• clarithromycin
Vraylar (cariprazine)

+

clarithromycin

1 interaction

Avoid/Use Alternative

cariprazine + clarithromycin

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING CLARITHROMYCIN: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• clofazimine
Vraylar (cariprazine)

+

clofazimine

1 interaction

Avoid/Use Alternative

cariprazine + clofazimine

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING CLOFAZIMINE: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• clonidine
Vraylar (cariprazine)

+

clonidine

1 interaction

Avoid/Use Alternative

cariprazine + clonidine

if ADHD use, avoid combo; otherwise, monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• cobicistat
Vraylar (cariprazine)

+

cobicistat

1 interaction

Avoid/Use Alternative

cariprazine + cobicistat

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING COBICISTAT: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• codeine
Vraylar (cariprazine)

+

codeine

1 interaction

Avoid/Use Alternative

cariprazine + codeine

avoid combo if antitussive use; otherwise monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• conivaptan
Vraylar (cariprazine)

+

conivaptan

1 interaction

Avoid/Use Alternative

cariprazine + conivaptan

during and x7 days after conivaptan: IF STARTING CARIPRAZINE: ADULTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS: avoid combo; IF STABLE CARIPRAZINE AND STARTING CONIVAPTAN: ADULT/PEDS, ALL USES: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• crizotinib
Vraylar (cariprazine)

+

crizotinib

1 interaction

Avoid/Use Alternative

cariprazine + crizotinib

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING CRIZOTINIB: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• cyclosporine
Vraylar (cariprazine)

+

cyclosporine

1 interaction

Avoid/Use Alternative

cariprazine + cyclosporine

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING CYCLOSPORINE: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• dabrafenib
Vraylar (cariprazine)

+

dabrafenib

1 interaction

Avoid/Use Alternative

cariprazine + dabrafenib

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• danazol
Vraylar (cariprazine)

+

danazol

1 interaction

Avoid/Use Alternative

cariprazine + danazol

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING DANAZOL: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• darunavir
Vraylar (cariprazine)

+

darunavir

1 interaction

Avoid/Use Alternative

cariprazine + darunavir

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING DARUNAVIR: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• diltiazem
Vraylar (cariprazine)

+

diltiazem

1 interaction

Avoid/Use Alternative

cariprazine + diltiazem

monitor BP; IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF STABLE CARIPRAZINE TX AND STARTING DILTIAZEM: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• doxylamine
Vraylar (cariprazine)

+

doxylamine

1 interaction

Avoid/Use Alternative

cariprazine + doxylamine

avoid combo if doxylamine use for pregnancy-related nausea/vomiting, otherwise caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• dronedarone
Vraylar (cariprazine)

+

dronedarone

1 interaction

Avoid/Use Alternative

cariprazine + dronedarone

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING DRONEDARONE: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• duvelisib
Vraylar (cariprazine)

+

duvelisib

1 interaction

Avoid/Use Alternative

cariprazine + duvelisib

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING DUVELISIB: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• efavirenz
Vraylar (cariprazine)

+

efavirenz

1 interaction

Avoid/Use Alternative

cariprazine + efavirenz

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• elagolix
Vraylar (cariprazine)

+

elagolix

1 interaction

Avoid/Use Alternative

cariprazine + elagolix

if elagolix 300 mg bid regimen, avoid combo; elagolix 200 mg bid regimen or 150 mg qd regimen OK: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• encorafenib
Vraylar (cariprazine)

+

encorafenib

1 interaction

Avoid/Use Alternative

cariprazine + encorafenib

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• enzalutamide
Vraylar (cariprazine)

+

enzalutamide

1 interaction

Avoid/Use Alternative

cariprazine + enzalutamide

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• erythromycin
Vraylar (cariprazine)

+

erythromycin

1 interaction

Avoid/Use Alternative

cariprazine + erythromycin

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING ERYTHROMYCIN: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• ethanol (alcoholic beverage)
Vraylar (cariprazine)

+

ethanol (alcoholic beverage)

1 interaction

Avoid/Use Alternative

cariprazine + ethanol (alcoholic beverage)

avoid combo: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• ethanol injection
Vraylar (cariprazine)

+

ethanol injection

1 interaction

Avoid/Use Alternative

cariprazine + ethanol injection

use alternative or monitor respiratory rate, BP: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• etravirine
Vraylar (cariprazine)

+

etravirine

1 interaction

Avoid/Use Alternative

cariprazine + etravirine

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• fedratinib
Vraylar (cariprazine)

+

fedratinib

1 interaction

Avoid/Use Alternative

cariprazine + fedratinib

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING FEDRATINIB: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• fexinidazole
Vraylar (cariprazine)

+

fexinidazole

1 interaction

Avoid/Use Alternative

cariprazine + fexinidazole

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• fluconazole
Vraylar (cariprazine)

+

fluconazole

1 interaction

Avoid/Use Alternative

cariprazine + fluconazole

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING FLUCONAZOLE: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• fosamprenavir
Vraylar (cariprazine)

+

fosamprenavir

1 interaction

Avoid/Use Alternative

cariprazine + fosamprenavir

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING FOSAMPRENAVIR: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• fosphenytoin
Vraylar (cariprazine)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

cariprazine + fosphenytoin

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy; may alter seizure control; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; antagonistic effects, cariprazine may decr. seizure threshold; additive effects)

• grapefruit
Vraylar (cariprazine)

+

grapefruit

1 interaction

Avoid/Use Alternative

cariprazine + grapefruit

avoid grapefruit juice: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (GI metabolism inhibited)

• haloperidol
Vraylar (cariprazine)

+

haloperidol

1 interaction

Avoid/Use Alternative

cariprazine + haloperidol

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hypotension, including orthostasis, syncope (additive effects)

• hydrocodone
Vraylar (cariprazine)

+

hydrocodone

1 interaction

Avoid/Use Alternative

cariprazine + hydrocodone

avoid combo if antitussive use; otherwise monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• idelalisib
Vraylar (cariprazine)

+

idelalisib

1 interaction

Avoid/Use Alternative

cariprazine + idelalisib

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING IDELALISIB: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• iloperidone
Vraylar (cariprazine)

+

iloperidone

1 interaction

Avoid/Use Alternative

cariprazine + iloperidone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• imatinib
Vraylar (cariprazine)

+

imatinib

1 interaction

Avoid/Use Alternative

cariprazine + imatinib

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING IMATINIB: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• isavuconazonium
Vraylar (cariprazine)

+

isavuconazonium

1 interaction

Avoid/Use Alternative

cariprazine + isavuconazonium

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING ISAVUCONAZONIUM: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• isocarboxazid
Vraylar (cariprazine)

+

isocarboxazid

1 interaction

Avoid/Use Alternative

cariprazine + isocarboxazid

use alternative during and x10 days after isocarboxazid use: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• itraconazole
Vraylar (cariprazine)

+

itraconazole

1 interaction

Avoid/Use Alternative

cariprazine + itraconazole

IF STARTING CARIPRAZINE: ADULTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS: avoid combo during and x2wk after itraconazole tx; IF ON STABLE CARIPRAZINE AND STARTING ITRACONAZOLE: ADULT AND PEDS, ALL USES: adjust cariprazine dose as: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• ivosidenib
Vraylar (cariprazine)

+

ivosidenib

1 interaction

Avoid/Use Alternative

cariprazine + ivosidenib

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• kava
Vraylar (cariprazine)

+

kava

1 interaction

Avoid/Use Alternative

cariprazine + kava

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms (additive effects)

• ketoconazole
Vraylar (cariprazine)

+

ketoconazole

1 interaction

Avoid/Use Alternative

cariprazine + ketoconazole

IF STARTING CARIPRAZINE: ADULTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS: avoid combo during and up to 1wk after ketoconazole; IF STABLE CARIPRAZINE AND STARTING KETOCONAZOLE: ADULT AND PEDS, ALL USES: adjust cariprazine dose as: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• kratom
Vraylar (cariprazine)

+

kratom

1 interaction

Avoid/Use Alternative

cariprazine + kratom

use alternative or monitor respiratory rate: combo may incr. cariprazine and active metabolite levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• lefamulin
Vraylar (cariprazine)

+

lefamulin

1 interaction

Avoid/Use Alternative

cariprazine + lefamulin

IV lefamulin use OK; for ORAL LEFAMULIN: IF STARTING CARIPRAZINE: ADULTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS: avoid combo; IF STABLE CARIPRAZINE AND STARTING ORAL LEFAMULIN: ADULT/PEDS, ALL USES: adjust cariprazine dose as: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• lenacapavir
Vraylar (cariprazine)

+

lenacapavir

1 interaction

Avoid/Use Alternative

cariprazine + lenacapavir

during and x9mo after lenacapavir: IF STARTING CARIPRAZINE: ADULTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS: avoid combo; IF ON STABLE CARIPRAZINE AND STARTING LENACAPAVIR: ADULT/PEDS, ALL USES: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• letermovir
Vraylar (cariprazine)

+

letermovir

1 interaction

Avoid/Use Alternative

cariprazine + letermovir

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING LETERMOVIR: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• levoketoconazole
Vraylar (cariprazine)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

cariprazine + levoketoconazole

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING LEVOKETOCONAZOLE: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• lofexidine
Vraylar (cariprazine)

+

lofexidine

1 interaction

Avoid/Use Alternative

cariprazine + lofexidine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• lonafarnib
Vraylar (cariprazine)

+

lonafarnib

1 interaction

Avoid/Use Alternative

cariprazine + lonafarnib

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING LONAFARNIB: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• lopinavir/ritonavir
Vraylar (cariprazine)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

cariprazine + lopinavir/ ritonavir

use alternative or consider cariprazine dose adjustment: combo may incr. or decr. cariprazine and active metabolite levels, other adverse effects or decr. efficacy (hepatic metabolism altered)

• lorlatinib
Vraylar (cariprazine)

+

lorlatinib

1 interaction

Avoid/Use Alternative

cariprazine + lorlatinib

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• lumacaftor/ivacaftor
Vraylar (cariprazine)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

cariprazine + lumacaftor/ ivacaftor

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• lumateperone
Vraylar (cariprazine)

+

lumateperone

1 interaction

Avoid/Use Alternative

cariprazine + lumateperone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• lurasidone
Vraylar (cariprazine)

+

lurasidone

1 interaction

Avoid/Use Alternative

cariprazine + lurasidone

use alternative or monitor BP; consider lowest lurasidone start dose, titrate slowly: combo may incr. cariprazine and active metabolite levels, risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects, duplicate therapy)

• mavacamten
Vraylar (cariprazine)

+

mavacamten

1 interaction

Avoid/Use Alternative

cariprazine + mavacamten

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• metaxalone
Vraylar (cariprazine)

+

metaxalone

1 interaction

Avoid/Use Alternative

cariprazine + metaxalone

use alternative or monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• metoclopramide
Vraylar (cariprazine)

+

metoclopramide

1 interaction

Avoid/Use Alternative

cariprazine + metoclopramide

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, neuroleptic malignant syndrome, extrapyramidal symptoms (additive effects)

• midazolam
Vraylar (cariprazine)

+

midazolam

1 interaction

Avoid/Use Alternative

cariprazine + midazolam

use alternative or monitor respiratory rate, BP; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope; may alter seizure control (additive effects; antagonistic effects, cariprazine may decr. seizure threshold)

• mifepristone
Vraylar (cariprazine)

+

mifepristone

1 interaction

Avoid/Use Alternative

cariprazine + mifepristone

during and x2wk after daily mifepristone use: IF STARTING CARIPRAZINE: ADULTS: adjust dose as: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS: avoid combo; IF STABLE CARIPRAZINE AND STARTING DAILY MIFEPRISTONE: ADULT/PEDS, ALL USES: adjust cariprazine dose as: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• milsaperidone
Vraylar (cariprazine)

+

milsaperidone

1 interaction

Avoid/Use Alternative

cariprazine + milsaperidone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• mitapivat
Vraylar (cariprazine)

+

mitapivat

1 interaction

Avoid/Use Alternative

cariprazine + mitapivat

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• mitotane
Vraylar (cariprazine)

+

mitotane

1 interaction

Avoid/Use Alternative

cariprazine + mitotane

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• modafinil
Vraylar (cariprazine)

+

modafinil

1 interaction

Avoid/Use Alternative

cariprazine + modafinil

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• nafcillin
Vraylar (cariprazine)

+

nafcillin

1 interaction

Avoid/Use Alternative

cariprazine + nafcillin

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• nefazodone
Vraylar (cariprazine)

+

nefazodone

1 interaction

Avoid/Use Alternative

cariprazine + nefazodone

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING NEFAZODONE: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• nelfinavir
Vraylar (cariprazine)

+

nelfinavir

1 interaction

Avoid/Use Alternative

cariprazine + nelfinavir

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING NELFINAVIR: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• netupitant
Vraylar (cariprazine)

+

netupitant

1 interaction

Avoid/Use Alternative

cariprazine + netupitant

during and x1wk after (fos)netupitant: IF STARTING CARIPRAZINE: ADULTS: adjust dose as: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS: avoid combo; IF ON STABLE CARIPRAZINE AND STARTING (FOS)NETUPITANT: ADULT/PEDS, ALL USES: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• nilotinib
Vraylar (cariprazine)

+

nilotinib

1 interaction

Avoid/Use Alternative

cariprazine + nilotinib

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING NILOTINIB: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• nirogacestat
Vraylar (cariprazine)

+

nirogacestat

1 interaction

Avoid/Use Alternative

cariprazine + nirogacestat

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING NIROGACESTAT: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• olanzapine
Vraylar (cariprazine)

+

olanzapine

1 interaction

Avoid/Use Alternative

cariprazine + olanzapine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• oxybate
Vraylar (cariprazine)

+

oxybate

1 interaction

Avoid/Use Alternative

cariprazine + oxybate

use alternative or monitor respiratory rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, syncope (additive effects)

• pacritinib
Vraylar (cariprazine)

+

pacritinib

1 interaction

Avoid/Use Alternative

cariprazine + pacritinib

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• pentobarbital
Vraylar (cariprazine)

+

pentobarbital

1 interaction

Avoid/Use Alternative

cariprazine + pentobarbital

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (hepatic metabolism induced; additive effects)

• pexidartinib
Vraylar (cariprazine)

+

pexidartinib

1 interaction

Avoid/Use Alternative

cariprazine + pexidartinib

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• phenelzine
Vraylar (cariprazine)

+

phenelzine

1 interaction

Avoid/Use Alternative

cariprazine + phenelzine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• phenobarbital
Vraylar (cariprazine)

+

phenobarbital

1 interaction

Avoid/Use Alternative

cariprazine + phenobarbital

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, cariprazine may decr. seizure threshold)

• phenytoin
Vraylar (cariprazine)

+

phenytoin

1 interaction

Avoid/Use Alternative

cariprazine + phenytoin

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy; may alter seizure control; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; antagonistic effects, cariprazine may decr. seizure threshold; additive effects)

• pitolisant
Vraylar (cariprazine)

+

pitolisant

1 interaction

Avoid/Use Alternative

cariprazine + pitolisant

avoid combo: combo may decr. pitolisant efficacy (antagonistic effects)

• posaconazole
Vraylar (cariprazine)

+

posaconazole

1 interaction

Avoid/Use Alternative

cariprazine + posaconazole

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING POSACONAZOLE: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• primidone
Vraylar (cariprazine)

+

primidone

1 interaction

Avoid/Use Alternative

cariprazine + primidone

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy; may alter seizure control; may incr. risk of CNS and respiratory depression, psychomotor impairment (hepatic metabolism induced; antagonistic effects, cariprazine may decr. seizure threshold; additive effects)

• promethazine
Vraylar (cariprazine)

+

promethazine

1 interaction

Avoid/Use Alternative

cariprazine + promethazine

use alternative or monitor BP, respiratory rate; decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension (including orthostasis, syncope), extrapyramidal symptoms, hyperthermia, seizures (additive effects)

• relacorilant
Vraylar (cariprazine)

+

relacorilant

1 interaction

Avoid/Use Alternative

cariprazine + relacorilant

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING RELACORILANT: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• repotrectinib
Vraylar (cariprazine)

+

repotrectinib

1 interaction

Avoid/Use Alternative

cariprazine + repotrectinib

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• ribociclib
Vraylar (cariprazine)

+

ribociclib

1 interaction

Avoid/Use Alternative

cariprazine + ribociclib

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING RIBOCICLIB: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg q: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• rifabutin
Vraylar (cariprazine)

+

rifabutin

1 interaction

Avoid/Use Alternative

cariprazine + rifabutin

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• rifampin
Vraylar (cariprazine)

+

rifampin

1 interaction

Avoid/Use Alternative

cariprazine + rifampin

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• rifapentine
Vraylar (cariprazine)

+

rifapentine

1 interaction

Avoid/Use Alternative

cariprazine + rifapentine

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• rilzabrutinib
Vraylar (cariprazine)

+

rilzabrutinib

1 interaction

Avoid/Use Alternative

cariprazine + rilzabrutinib

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING RILZABRUTINIB: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• ritonavir
Vraylar (cariprazine)

+

ritonavir

1 interaction

Avoid/Use Alternative

cariprazine + ritonavir

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING RITONAVIR: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg q: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• ropeginterferon alfa-2b
Vraylar (cariprazine)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

cariprazine + ropeginterferon alfa-2b

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• scopolamine
Vraylar (cariprazine)

+

scopolamine

1 interaction

Avoid/Use Alternative

cariprazine + scopolamine

use alternative: combo may increase risk of CNS depression, psychomotor impairment, hyperthermia, including life-threatening (additive effects)

• sotorasib
Vraylar (cariprazine)

+

sotorasib

1 interaction

Avoid/Use Alternative

cariprazine + sotorasib

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• St. John's wort
Vraylar (cariprazine)

+

St. John's wort

1 interaction

Avoid/Use Alternative

cariprazine + St. John's wort

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• thalidomide
Vraylar (cariprazine)

+

thalidomide

1 interaction

Avoid/Use Alternative

cariprazine + thalidomide

use alternative or monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• tipranavir
Vraylar (cariprazine)

+

tipranavir

1 interaction

Avoid/Use Alternative

cariprazine + tipranavir

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING TIPRANAVIR: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• tradipitant
Vraylar (cariprazine)

+

tradipitant

1 interaction

Avoid/Use Alternative

cariprazine + tradipitant

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tranylcypromine
Vraylar (cariprazine)

+

tranylcypromine

1 interaction

Avoid/Use Alternative

cariprazine + tranylcypromine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• trimethobenzamide
Vraylar (cariprazine)

+

trimethobenzamide

1 interaction

Avoid/Use Alternative

cariprazine + trimethobenzamide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms (additive effects)

• tucatinib
Vraylar (cariprazine)

+

tucatinib

1 interaction

Avoid/Use Alternative

cariprazine + tucatinib

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING TUCATINIB: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• verapamil
Vraylar (cariprazine)

+

verapamil

1 interaction

Avoid/Use Alternative

cariprazine + verapamil

monitor BP; IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF STABLE CARIPRAZINE TX AND STARTING VERAPAMIL: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• voriconazole
Vraylar (cariprazine)

+

voriconazole

1 interaction

Avoid/Use Alternative

cariprazine + voriconazole

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING VORICONAZOLE: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• ziprasidone
Vraylar (cariprazine)

+

ziprasidone

1 interaction

Avoid/Use Alternative

cariprazine + ziprasidone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• zuranolone
Vraylar (cariprazine)

+

zuranolone

1 interaction

Avoid/Use Alternative

cariprazine + zuranolone

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Monitor/Modify Tx

• acarbose
Vraylar (cariprazine)

+

acarbose

1 interaction

Monitor/Modify Tx

cariprazine + acarbose

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• acebutolol
Vraylar (cariprazine)

+

acebutolol

1 interaction

Monitor/Modify Tx

cariprazine + acebutolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• alfentanil
Vraylar (cariprazine)

+

alfentanil

1 interaction

Monitor/Modify Tx

cariprazine + alfentanil

monitor BP, respiratory rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• alfuzosin
Vraylar (cariprazine)

+

alfuzosin

1 interaction

Monitor/Modify Tx

cariprazine + alfuzosin

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• aliskiren
Vraylar (cariprazine)

+

aliskiren

1 interaction

Monitor/Modify Tx

cariprazine + aliskiren

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• alogliptin
Vraylar (cariprazine)

+

alogliptin

1 interaction

Monitor/Modify Tx

cariprazine + alogliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• alprazolam
Vraylar (cariprazine)

+

alprazolam

1 interaction

Monitor/Modify Tx

cariprazine + alprazolam

monitor respiratory rate, BP: combo may incr. cariprazine and active metabolite levels, risk of CNS and respiratory depression, psychomotor impairment, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• alprostadil intracavernous
Vraylar (cariprazine)

+

alprostadil intracavernous

1 interaction

Monitor/Modify Tx

cariprazine + alprostadil intracavernous

monitor BP: combo may increase risk of hypotension, including orthostasis, syncope (additive effects)

• amantadine
Vraylar (cariprazine)

+

amantadine

1 interaction

Monitor/Modify Tx

cariprazine + amantadine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• amifostine
Vraylar (cariprazine)

+

amifostine

1 interaction

Monitor/Modify Tx

cariprazine + amifostine

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• amiloride
Vraylar (cariprazine)

+

amiloride

1 interaction

Monitor/Modify Tx

cariprazine + amiloride

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• amitriptyline
Vraylar (cariprazine)

+

amitriptyline

1 interaction

Monitor/Modify Tx

cariprazine + amitriptyline

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• amlodipine
Vraylar (cariprazine)

+

amlodipine

1 interaction

Monitor/Modify Tx

cariprazine + amlodipine

monitor BP: combo may incr. cariprazine and active metabolite levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• amoxapine
Vraylar (cariprazine)

+

amoxapine

1 interaction

Monitor/Modify Tx

cariprazine + amoxapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• apomorphine
Vraylar (cariprazine)

+

apomorphine

1 interaction

Monitor/Modify Tx

cariprazine + apomorphine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• apraclonidine ophthalmic
Vraylar (cariprazine)

+

apraclonidine ophthalmic

1 interaction

Monitor/Modify Tx

cariprazine + apraclonidine ophthalmic

monitor BP if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• aprocitentan
Vraylar (cariprazine)

+

aprocitentan

1 interaction

Monitor/Modify Tx

cariprazine + aprocitentan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• articaine
Vraylar (cariprazine)

+

articaine

1 interaction

Monitor/Modify Tx

cariprazine + articaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• atenolol
Vraylar (cariprazine)

+

atenolol

1 interaction

Monitor/Modify Tx

cariprazine + atenolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• avanafil
Vraylar (cariprazine)

+

avanafil

1 interaction

Monitor/Modify Tx

cariprazine + avanafil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• azilsartan medoxomil
Vraylar (cariprazine)

+

azilsartan medoxomil

1 interaction

Monitor/Modify Tx

cariprazine + azilsartan medoxomil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• benazepril
Vraylar (cariprazine)

+

benazepril

1 interaction

Monitor/Modify Tx

cariprazine + benazepril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• berberine
Vraylar (cariprazine)

+

berberine

1 interaction

Monitor/Modify Tx

cariprazine + berberine

monitor BP: combo may incr. cariprazine and active metabolite levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• betaxolol
Vraylar (cariprazine)

+

betaxolol

1 interaction

Monitor/Modify Tx

cariprazine + betaxolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• betaxolol ophthalmic
Vraylar (cariprazine)

+

betaxolol ophthalmic

1 interaction

Monitor/Modify Tx

cariprazine + betaxolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bethanechol
Vraylar (cariprazine)

+

bethanechol

1 interaction

Monitor/Modify Tx

cariprazine + bethanechol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bexagliflozin
Vraylar (cariprazine)

+

bexagliflozin

1 interaction

Monitor/Modify Tx

cariprazine + bexagliflozin

monitor glucose, BP: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• bisoprolol
Vraylar (cariprazine)

+

bisoprolol

1 interaction

Monitor/Modify Tx

cariprazine + bisoprolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bortezomib
Vraylar (cariprazine)

+

bortezomib

1 interaction

Monitor/Modify Tx

cariprazine + bortezomib

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• brexpiprazole
Vraylar (cariprazine)

+

brexpiprazole

1 interaction

Monitor/Modify Tx

cariprazine + brexpiprazole

monitor BP: combo may incr. risk of hypotension (including orthostasis, syncope), CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia (additive effects, duplicate therapy)

• brimonidine ophthalmic
Vraylar (cariprazine)

+

brimonidine ophthalmic

1 interaction

Monitor/Modify Tx

cariprazine + brimonidine ophthalmic

monitor BP if elevated IOP or presbyopia use; OTC ocular redness use OK: combo may increase risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• brimonidine topical
Vraylar (cariprazine)

+

brimonidine topical

1 interaction

Monitor/Modify Tx

cariprazine + brimonidine topical

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• bromocriptine
Vraylar (cariprazine)

+

bromocriptine

1 interaction

Monitor/Modify Tx

cariprazine + bromocriptine

monitor BP, glucose in type 2 diabetes mellitus pts: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• bumetanide
Vraylar (cariprazine)

+

bumetanide

1 interaction

Monitor/Modify Tx

cariprazine + bumetanide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bupivacaine
Vraylar (cariprazine)

+

bupivacaine

1 interaction

Monitor/Modify Tx

cariprazine + bupivacaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bupivacaine liposomal
Vraylar (cariprazine)

+

bupivacaine liposomal

1 interaction

Monitor/Modify Tx

cariprazine + bupivacaine liposomal

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• buprenorphine
Vraylar (cariprazine)

+

buprenorphine

1 interaction

Monitor/Modify Tx

cariprazine + buprenorphine

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• bupropion
Vraylar (cariprazine)

+

bupropion

1 interaction

Monitor/Modify Tx

cariprazine + bupropion

consider lower bupropion doses: combo may incr. risk of seizures (additive effects)

• butorphanol
Vraylar (cariprazine)

+

butorphanol

1 interaction

Monitor/Modify Tx

cariprazine + butorphanol

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• cabergoline
Vraylar (cariprazine)

+

cabergoline

1 interaction

Monitor/Modify Tx

cariprazine + cabergoline

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• canagliflozin
Vraylar (cariprazine)

+

canagliflozin

1 interaction

Monitor/Modify Tx

cariprazine + canagliflozin

monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• candesartan cilexetil
Vraylar (cariprazine)

+

candesartan cilexetil

1 interaction

Monitor/Modify Tx

cariprazine + candesartan cilexetil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• cannabis
Vraylar (cariprazine)

+

cannabis

1 interaction

Monitor/Modify Tx

cariprazine + cannabis

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• captopril
Vraylar (cariprazine)

+

captopril

1 interaction

Monitor/Modify Tx

cariprazine + captopril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• carteolol ophthalmic
Vraylar (cariprazine)

+

carteolol ophthalmic

1 interaction

Monitor/Modify Tx

cariprazine + carteolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• carvedilol
Vraylar (cariprazine)

+

carvedilol

1 interaction

Monitor/Modify Tx

cariprazine + carvedilol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• chlordiazepoxide
Vraylar (cariprazine)

+

chlordiazepoxide

1 interaction

Monitor/Modify Tx

cariprazine + chlordiazepoxide

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• chloroprocaine
Vraylar (cariprazine)

+

chloroprocaine

1 interaction

Monitor/Modify Tx

cariprazine + chloroprocaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• chlorothiazide
Vraylar (cariprazine)

+

chlorothiazide

1 interaction

Monitor/Modify Tx

cariprazine + chlorothiazide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• chlorpromazine
Vraylar (cariprazine)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

cariprazine + chlorpromazine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), extrapyramidal symptoms, hyperthermia (additive effects)

• chlorthalidone
Vraylar (cariprazine)

+

chlorthalidone

1 interaction

Monitor/Modify Tx

cariprazine + chlorthalidone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• cilostazol
Vraylar (cariprazine)

+

cilostazol

1 interaction

Monitor/Modify Tx

cariprazine + cilostazol

monitor BP: combo may incr. cariprazine and active metabolite levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• clevidipine
Vraylar (cariprazine)

+

clevidipine

1 interaction

Monitor/Modify Tx

cariprazine + clevidipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• clobazam
Vraylar (cariprazine)

+

clobazam

1 interaction

Monitor/Modify Tx

cariprazine + clobazam

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope; may alter seizure control (additive effects; antagonistic effects, cariprazine may decr. seizure threshold)

• clofarabine
Vraylar (cariprazine)

+

clofarabine

1 interaction

Monitor/Modify Tx

cariprazine + clofarabine

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• clomipramine
Vraylar (cariprazine)

+

clomipramine

1 interaction

Monitor/Modify Tx

cariprazine + clomipramine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, seizures, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• clonazepam
Vraylar (cariprazine)

+

clonazepam

1 interaction

Monitor/Modify Tx

cariprazine + clonazepam

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope; may alter seizure control (additive effects; antagonistic effects, cariprazine may decr. seizure threshold)

• clorazepate
Vraylar (cariprazine)

+

clorazepate

1 interaction

Monitor/Modify Tx

cariprazine + clorazepate

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope; may alter seizure control (additive effects; antagonistic effects, cariprazine may decr. seizure threshold)

• clozapine
Vraylar (cariprazine)

+

clozapine

1 interaction

Monitor/Modify Tx

cariprazine + clozapine

monitor BP, HR: combo may incr. risk of CNS depression, psychomotor impairment, seizures, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects, duplicate therapy)

• coenzyme Q-10
Vraylar (cariprazine)

+

coenzyme Q-10

1 interaction

Monitor/Modify Tx

cariprazine + coenzyme Q-10

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• colesevelam
Vraylar (cariprazine)

+

colesevelam

1 interaction

Monitor/Modify Tx

cariprazine + colesevelam

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• dapagliflozin
Vraylar (cariprazine)

+

dapagliflozin

1 interaction

Monitor/Modify Tx

cariprazine + dapagliflozin

monitor glucose, BP: combo may decr. antidiabetic agent efficacy; may incr. risk of hypotension, including orthostasis, syncope (antagonistic effects; additive effects)

• daridorexant
Vraylar (cariprazine)

+

daridorexant

1 interaction

Monitor/Modify Tx

cariprazine + daridorexant

consider decr. dose of one or both drugs: combo may incr. cariprazine and active metabolite levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• denileukin diftitox
Vraylar (cariprazine)

+

denileukin diftitox

1 interaction

Monitor/Modify Tx

cariprazine + denileukin diftitox

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• desflurane
Vraylar (cariprazine)

+

desflurane

1 interaction

Monitor/Modify Tx

cariprazine + desflurane

monitor respiratory rate, BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• desipramine
Vraylar (cariprazine)

+

desipramine

1 interaction

Monitor/Modify Tx

cariprazine + desipramine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• dexmedetomidine
Vraylar (cariprazine)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

cariprazine + dexmedetomidine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• dexmedetomidine injection
Vraylar (cariprazine)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

cariprazine + dexmedetomidine injection

monitor BP, respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

• diazepam
Vraylar (cariprazine)

+

diazepam

1 interaction

Monitor/Modify Tx

cariprazine + diazepam

monitor respiratory rate, BP; use lowest effective doses and shortest duration of concomitant tx: combo may alter seizure control; may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (antagonistic effects, cariprazine may decr. seizure threshold; additive effects)

• dihydrocodeine
Vraylar (cariprazine)

+

dihydrocodeine

1 interaction

Monitor/Modify Tx

cariprazine + dihydrocodeine

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• dinutuximab
Vraylar (cariprazine)

+

dinutuximab

1 interaction

Monitor/Modify Tx

cariprazine + dinutuximab

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• dipyridamole
Vraylar (cariprazine)

+

dipyridamole

1 interaction

Monitor/Modify Tx

cariprazine + dipyridamole

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• doxazosin
Vraylar (cariprazine)

+

doxazosin

1 interaction

Monitor/Modify Tx

cariprazine + doxazosin

monitor BP, especially during doxazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• doxepin
Vraylar (cariprazine)

+

doxepin

1 interaction

Monitor/Modify Tx

cariprazine + doxepin

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• dronabinol
Vraylar (cariprazine)

+

dronabinol

1 interaction

Monitor/Modify Tx

cariprazine + dronabinol

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• droperidol
Vraylar (cariprazine)

+

droperidol

1 interaction

Monitor/Modify Tx

cariprazine + droperidol

decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dulaglutide
Vraylar (cariprazine)

+

dulaglutide

1 interaction

Monitor/Modify Tx

cariprazine + dulaglutide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• duloxetine
Vraylar (cariprazine)

+

duloxetine

1 interaction

Monitor/Modify Tx

cariprazine + duloxetine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• empagliflozin
Vraylar (cariprazine)

+

empagliflozin

1 interaction

Monitor/Modify Tx

cariprazine + empagliflozin

monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• enalapril
Vraylar (cariprazine)

+

enalapril

1 interaction

Monitor/Modify Tx

cariprazine + enalapril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• enalaprilat
Vraylar (cariprazine)

+

enalaprilat

1 interaction

Monitor/Modify Tx

cariprazine + enalaprilat

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• entacapone
Vraylar (cariprazine)

+

entacapone

1 interaction

Monitor/Modify Tx

cariprazine + entacapone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• entrectinib
Vraylar (cariprazine)

+

entrectinib

1 interaction

Monitor/Modify Tx

cariprazine + entrectinib

monitor BP: combo may incr. cariprazine and active metabolite levels, risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• eplerenone
Vraylar (cariprazine)

+

eplerenone

1 interaction

Monitor/Modify Tx

cariprazine + eplerenone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• epoprostenol
Vraylar (cariprazine)

+

epoprostenol

1 interaction

Monitor/Modify Tx

cariprazine + epoprostenol

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• ertugliflozin
Vraylar (cariprazine)

+

ertugliflozin

1 interaction

Monitor/Modify Tx

cariprazine + ertugliflozin

monitor glucose, BP: combo may decr. antidiabetic agent efficacy; may incr. risk of hypotension, including orthostasis, syncope (antagonistic effects; additive effects)

• esketamine
Vraylar (cariprazine)

+

esketamine

1 interaction

Monitor/Modify Tx

cariprazine + esketamine

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• esmolol
Vraylar (cariprazine)

+

esmolol

1 interaction

Monitor/Modify Tx

cariprazine + esmolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• estazolam
Vraylar (cariprazine)

+

estazolam

1 interaction

Monitor/Modify Tx

cariprazine + estazolam

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• eszopiclone
Vraylar (cariprazine)

+

eszopiclone

1 interaction

Monitor/Modify Tx

cariprazine + eszopiclone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ethacrynic acid
Vraylar (cariprazine)

+

ethacrynic acid

1 interaction

Monitor/Modify Tx

cariprazine + ethacrynic acid

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• ethanol (in some formulations)
Vraylar (cariprazine)

+

ethanol (in some formulations)

1 interaction

Monitor/Modify Tx

cariprazine + ethanol (in some formulations)

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• etomidate
Vraylar (cariprazine)

+

etomidate

1 interaction

Monitor/Modify Tx

cariprazine + etomidate

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• etripamil nasal
Vraylar (cariprazine)

+

etripamil nasal

1 interaction

Monitor/Modify Tx

cariprazine + etripamil nasal

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• exenatide
Vraylar (cariprazine)

+

exenatide

1 interaction

Monitor/Modify Tx

cariprazine + exenatide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• felodipine
Vraylar (cariprazine)

+

felodipine

1 interaction

Monitor/Modify Tx

cariprazine + felodipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• fenoldopam
Vraylar (cariprazine)

+

fenoldopam

1 interaction

Monitor/Modify Tx

cariprazine + fenoldopam

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• fentanyl
Vraylar (cariprazine)

+

fentanyl

1 interaction

Monitor/Modify Tx

cariprazine + fentanyl

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• ferumoxytol
Vraylar (cariprazine)

+

ferumoxytol

1 interaction

Monitor/Modify Tx

cariprazine + ferumoxytol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• flaxseed
Vraylar (cariprazine)

+

flaxseed

1 interaction

Monitor/Modify Tx

cariprazine + flaxseed

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• flibanserin
Vraylar (cariprazine)

+

flibanserin

1 interaction

Monitor/Modify Tx

cariprazine + flibanserin

monitor BP: combo may incr. cariprazine and active metabolite levels, risk of CNS depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• fluphenazine
Vraylar (cariprazine)

+

fluphenazine

1 interaction

Monitor/Modify Tx

cariprazine + fluphenazine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), extrapyramidal symptoms, hyperthermia (additive effects)

• flurazepam
Vraylar (cariprazine)

+

flurazepam

1 interaction

Monitor/Modify Tx

cariprazine + flurazepam

monitor BP, respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• fosinopril
Vraylar (cariprazine)

+

fosinopril

1 interaction

Monitor/Modify Tx

cariprazine + fosinopril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• foslevodopa
Vraylar (cariprazine)

+

foslevodopa

1 interaction

Monitor/Modify Tx

cariprazine + foslevodopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• furosemide
Vraylar (cariprazine)

+

furosemide

1 interaction

Monitor/Modify Tx

cariprazine + furosemide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• gabapentin
Vraylar (cariprazine)

+

gabapentin

1 interaction

Monitor/Modify Tx

cariprazine + gabapentin

monitor respiratory rate; consider decreasing gabapentin dose: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cariprazine may decrease seizure threshold)

• gabapentin enacarbil
Vraylar (cariprazine)

+

gabapentin enacarbil

1 interaction

Monitor/Modify Tx

cariprazine + gabapentin enacarbil

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• garlic
Vraylar (cariprazine)

+

garlic

1 interaction

Monitor/Modify Tx

cariprazine + garlic

monitor BP w/ supplemental garlic; dietary intake OK: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• gilteritinib
Vraylar (cariprazine)

+

gilteritinib

1 interaction

Monitor/Modify Tx

cariprazine + gilteritinib

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• glimepiride
Vraylar (cariprazine)

+

glimepiride

1 interaction

Monitor/Modify Tx

cariprazine + glimepiride

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• glipizide
Vraylar (cariprazine)

+

glipizide

1 interaction

Monitor/Modify Tx

cariprazine + glipizide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• glyburide
Vraylar (cariprazine)

+

glyburide

1 interaction

Monitor/Modify Tx

cariprazine + glyburide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• guanfacine
Vraylar (cariprazine)

+

guanfacine

1 interaction

Monitor/Modify Tx

cariprazine + guanfacine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• hydralazine
Vraylar (cariprazine)

+

hydralazine

1 interaction

Monitor/Modify Tx

cariprazine + hydralazine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• hydrochlorothiazide
Vraylar (cariprazine)

+

hydrochlorothiazide

1 interaction

Monitor/Modify Tx

cariprazine + hydrochlorothiazide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• hydromorphone
Vraylar (cariprazine)

+

hydromorphone

1 interaction

Monitor/Modify Tx

cariprazine + hydromorphone

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• hydroxyzine
Vraylar (cariprazine)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

cariprazine + hydroxyzine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• ifosfamide
Vraylar (cariprazine)

+

ifosfamide

1 interaction

Monitor/Modify Tx

cariprazine + ifosfamide

D/C one or both drugs if encephalopathy occurs; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• iloprost
Vraylar (cariprazine)

+

iloprost

1 interaction

Monitor/Modify Tx

cariprazine + iloprost

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• imipramine
Vraylar (cariprazine)

+

imipramine

1 interaction

Monitor/Modify Tx

cariprazine + imipramine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• indapamide
Vraylar (cariprazine)

+

indapamide

1 interaction

Monitor/Modify Tx

cariprazine + indapamide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• insulin
Vraylar (cariprazine)

+

insulin

1 interaction

Monitor/Modify Tx

cariprazine + insulin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• iohexol
Vraylar (cariprazine)

+

iohexol

1 interaction

Monitor/Modify Tx

cariprazine + iohexol

if intrathecal iohexol use, D/C cariprazine at least 48h before myelography, may resume at least 24h after procedure: combo may incr. risk of seizures (additive effects)

• iopamidol
Vraylar (cariprazine)

+

iopamidol

1 interaction

Monitor/Modify Tx

cariprazine + iopamidol

caution advised if intrathecal iopamidol use; consider holding cariprazine at least 48h before and at least 24h after intrathecal iopamidol: combo may incr. risk of seizures (additive effects)

• irbesartan
Vraylar (cariprazine)

+

irbesartan

1 interaction

Monitor/Modify Tx

cariprazine + irbesartan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• iron sucrose
Vraylar (cariprazine)

+

iron sucrose

1 interaction

Monitor/Modify Tx

cariprazine + iron sucrose

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• isoflurane
Vraylar (cariprazine)

+

isoflurane

1 interaction

Monitor/Modify Tx

cariprazine + isoflurane

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• isosorbide dinitrate
Vraylar (cariprazine)

+

isosorbide dinitrate

1 interaction

Monitor/Modify Tx

cariprazine + isosorbide dinitrate

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• isosorbide mononitrate
Vraylar (cariprazine)

+

isosorbide mononitrate

1 interaction

Monitor/Modify Tx

cariprazine + isosorbide mononitrate

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• isradipine
Vraylar (cariprazine)

+

isradipine

1 interaction

Monitor/Modify Tx

cariprazine + isradipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• ketamine
Vraylar (cariprazine)

+

ketamine

1 interaction

Monitor/Modify Tx

cariprazine + ketamine

monitor respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression (including life-threatening), psychomotor impairment (additive effects)

• labetalol
Vraylar (cariprazine)

+

labetalol

1 interaction

Monitor/Modify Tx

cariprazine + labetalol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• landiolol
Vraylar (cariprazine)

+

landiolol

1 interaction

Monitor/Modify Tx

cariprazine + landiolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• lemborexant
Vraylar (cariprazine)

+

lemborexant

1 interaction

Monitor/Modify Tx

cariprazine + lemborexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levobunolol ophthalmic
Vraylar (cariprazine)

+

levobunolol ophthalmic

1 interaction

Monitor/Modify Tx

cariprazine + levobunolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• levodopa
Vraylar (cariprazine)

+

levodopa

1 interaction

Monitor/Modify Tx

cariprazine + levodopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• levorphanol
Vraylar (cariprazine)

+

levorphanol

1 interaction

Monitor/Modify Tx

cariprazine + levorphanol

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• lidocaine
Vraylar (cariprazine)

+

lidocaine

1 interaction

Monitor/Modify Tx

cariprazine + lidocaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• linagliptin
Vraylar (cariprazine)

+

linagliptin

1 interaction

Monitor/Modify Tx

cariprazine + linagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• liraglutide
Vraylar (cariprazine)

+

liraglutide

1 interaction

Monitor/Modify Tx

cariprazine + liraglutide

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• lisinopril
Vraylar (cariprazine)

+

lisinopril

1 interaction

Monitor/Modify Tx

cariprazine + lisinopril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• lithium
Vraylar (cariprazine)

+

lithium

1 interaction

Monitor/Modify Tx

cariprazine + lithium

D/C one or both drugs if encephalopathy occurs: combo may incr. risk of encephalopathic syndrome, extrapyramidal symptoms (additive effects)

• lixisenatide
Vraylar (cariprazine)

+

lixisenatide

1 interaction

Monitor/Modify Tx

cariprazine + lixisenatide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• lorazepam
Vraylar (cariprazine)

+

lorazepam

1 interaction

Monitor/Modify Tx

cariprazine + lorazepam

monitor respiratory rate, BP; use lowest effective doses and shortest duration of concomitant tx: combo may alter seizure control; may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (antagonistic effects, cariprazine may decr. seizure threshold; additive effects)

• losartan
Vraylar (cariprazine)

+

losartan

1 interaction

Monitor/Modify Tx

cariprazine + losartan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• loxapine
Vraylar (cariprazine)

+

loxapine

1 interaction

Monitor/Modify Tx

cariprazine + loxapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, extrapyramidal symptoms, hypotension, including orthostasis, syncope (additive effects)

• lubiprostone
Vraylar (cariprazine)

+

lubiprostone

1 interaction

Monitor/Modify Tx

cariprazine + lubiprostone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• magnesium sulfate
Vraylar (cariprazine)

+

magnesium sulfate

1 interaction

Monitor/Modify Tx

cariprazine + magnesium sulfate

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• maraviroc
Vraylar (cariprazine)

+

maraviroc

1 interaction

Monitor/Modify Tx

cariprazine + maraviroc

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• meperidine
Vraylar (cariprazine)

+

meperidine

1 interaction

Monitor/Modify Tx

cariprazine + meperidine

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• mepivacaine
Vraylar (cariprazine)

+

mepivacaine

1 interaction

Monitor/Modify Tx

cariprazine + mepivacaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• metformin
Vraylar (cariprazine)

+

metformin

1 interaction

Monitor/Modify Tx

cariprazine + metformin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• methadone
Vraylar (cariprazine)

+

methadone

1 interaction

Monitor/Modify Tx

cariprazine + methadone

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• methohexital
Vraylar (cariprazine)

+

methohexital

1 interaction

Monitor/Modify Tx

cariprazine + methohexital

monitor BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• methyldopa
Vraylar (cariprazine)

+

methyldopa

1 interaction

Monitor/Modify Tx

cariprazine + methyldopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• methylene blue injection
Vraylar (cariprazine)

+

methylene blue injection

1 interaction

Monitor/Modify Tx

cariprazine + methylene blue injection

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• metolazone
Vraylar (cariprazine)

+

metolazone

1 interaction

Monitor/Modify Tx

cariprazine + metolazone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• metoprolol
Vraylar (cariprazine)

+

metoprolol

1 interaction

Monitor/Modify Tx

cariprazine + metoprolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• miglitol
Vraylar (cariprazine)

+

miglitol

1 interaction

Monitor/Modify Tx

cariprazine + miglitol

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• milrinone
Vraylar (cariprazine)

+

milrinone

1 interaction

Monitor/Modify Tx

cariprazine + milrinone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• minoxidil
Vraylar (cariprazine)

+

minoxidil

1 interaction

Monitor/Modify Tx

cariprazine + minoxidil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• mirtazapine
Vraylar (cariprazine)

+

mirtazapine

1 interaction

Monitor/Modify Tx

cariprazine + mirtazapine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• moexipril
Vraylar (cariprazine)

+

moexipril

1 interaction

Monitor/Modify Tx

cariprazine + moexipril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• molindone
Vraylar (cariprazine)

+

molindone

1 interaction

Monitor/Modify Tx

cariprazine + molindone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, extrapyramidal symptoms, hypotension, including orthostasis, syncope (additive effects)

• morphine
Vraylar (cariprazine)

+

morphine

1 interaction

Monitor/Modify Tx

cariprazine + morphine

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• nadolol
Vraylar (cariprazine)

+

nadolol

1 interaction

Monitor/Modify Tx

cariprazine + nadolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nalbuphine
Vraylar (cariprazine)

+

nalbuphine

1 interaction

Monitor/Modify Tx

cariprazine + nalbuphine

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• nateglinide
Vraylar (cariprazine)

+

nateglinide

1 interaction

Monitor/Modify Tx

cariprazine + nateglinide

monitor glucose; consider incr. nateglinide dose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• nattokinase
Vraylar (cariprazine)

+

nattokinase

1 interaction

Monitor/Modify Tx

cariprazine + nattokinase

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• naxitamab
Vraylar (cariprazine)

+

naxitamab

1 interaction

Monitor/Modify Tx

cariprazine + naxitamab

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nebivolol
Vraylar (cariprazine)

+

nebivolol

1 interaction

Monitor/Modify Tx

cariprazine + nebivolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nelarabine
Vraylar (cariprazine)

+

nelarabine

1 interaction

Monitor/Modify Tx

cariprazine + nelarabine

withhold nelarabine if Grade 2 or greater somnolence occurs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• niacin (vitamin B3)
Vraylar (cariprazine)

+

niacin (vitamin B3)

1 interaction

Monitor/Modify Tx

cariprazine + niacin (vitamin B3)

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nicardipine
Vraylar (cariprazine)

+

nicardipine

1 interaction

Monitor/Modify Tx

cariprazine + nicardipine

monitor BP: combo may incr. cariprazine and active metabolite levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• nifedipine
Vraylar (cariprazine)

+

nifedipine

1 interaction

Monitor/Modify Tx

cariprazine + nifedipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nimodipine
Vraylar (cariprazine)

+

nimodipine

1 interaction

Monitor/Modify Tx

cariprazine + nimodipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nisoldipine
Vraylar (cariprazine)

+

nisoldipine

1 interaction

Monitor/Modify Tx

cariprazine + nisoldipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nitric oxide
Vraylar (cariprazine)

+

nitric oxide

1 interaction

Monitor/Modify Tx

cariprazine + nitric oxide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nitrite
Vraylar (cariprazine)

+

nitrite

1 interaction

Monitor/Modify Tx

cariprazine + nitrite

monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

• nitroglycerin
Vraylar (cariprazine)

+

nitroglycerin

1 interaction

Monitor/Modify Tx

cariprazine + nitroglycerin

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• nitroprusside
Vraylar (cariprazine)

+

nitroprusside

1 interaction

Monitor/Modify Tx

cariprazine + nitroprusside

monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

• nortriptyline
Vraylar (cariprazine)

+

nortriptyline

1 interaction

Monitor/Modify Tx

cariprazine + nortriptyline

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• obinutuzumab
Vraylar (cariprazine)

+

obinutuzumab

1 interaction

Monitor/Modify Tx

cariprazine + obinutuzumab

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• oliceridine
Vraylar (cariprazine)

+

oliceridine

1 interaction

Monitor/Modify Tx

cariprazine + oliceridine

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• olmesartan medoxomil
Vraylar (cariprazine)

+

olmesartan medoxomil

1 interaction

Monitor/Modify Tx

cariprazine + olmesartan medoxomil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• opicapone
Vraylar (cariprazine)

+

opicapone

1 interaction

Monitor/Modify Tx

cariprazine + opicapone

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• opium
Vraylar (cariprazine)

+

opium

1 interaction

Monitor/Modify Tx

cariprazine + opium

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• oxazepam
Vraylar (cariprazine)

+

oxazepam

1 interaction

Monitor/Modify Tx

cariprazine + oxazepam

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• oxybutynin
Vraylar (cariprazine)

+

oxybutynin

1 interaction

Monitor/Modify Tx

cariprazine + oxybutynin

decr. dose of one or both drugs or consider oxybutynin transdermal patch: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia; somnolence less likely with oxybutynin transdermal patch (additive effects)

• oxycodone
Vraylar (cariprazine)

+

oxycodone

1 interaction

Monitor/Modify Tx

cariprazine + oxycodone

monitor respiratory rate, BP; decr. oxycodone start dose by at least 50%, consider decr. cariprazine dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• oxymorphone
Vraylar (cariprazine)

+

oxymorphone

1 interaction

Monitor/Modify Tx

cariprazine + oxymorphone

monitor respiratory rate, BP; decr. oxymorphone start dose by at least 50%, consider decr. cariprazine dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• paliperidone
Vraylar (cariprazine)

+

paliperidone

1 interaction

Monitor/Modify Tx

cariprazine + paliperidone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects, duplicate therapy)

• palopegteriparatide
Vraylar (cariprazine)

+

palopegteriparatide

1 interaction

Monitor/Modify Tx

cariprazine + palopegteriparatide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• pentamidine
Vraylar (cariprazine)

+

pentamidine

1 interaction

Monitor/Modify Tx

cariprazine + pentamidine

monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

• pentazocine
Vraylar (cariprazine)

+

pentazocine

1 interaction

Monitor/Modify Tx

cariprazine + pentazocine

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• perindopril
Vraylar (cariprazine)

+

perindopril

1 interaction

Monitor/Modify Tx

cariprazine + perindopril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• perphenazine
Vraylar (cariprazine)

+

perphenazine

1 interaction

Monitor/Modify Tx

cariprazine + perphenazine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), extrapyramidal symptoms, hyperthermia (additive effects)

• phenoxybenzamine
Vraylar (cariprazine)

+

phenoxybenzamine

1 interaction

Monitor/Modify Tx

cariprazine + phenoxybenzamine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• phentolamine
Vraylar (cariprazine)

+

phentolamine

1 interaction

Monitor/Modify Tx

cariprazine + phentolamine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• pindolol
Vraylar (cariprazine)

+

pindolol

1 interaction

Monitor/Modify Tx

cariprazine + pindolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• pioglitazone
Vraylar (cariprazine)

+

pioglitazone

1 interaction

Monitor/Modify Tx

cariprazine + pioglitazone

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects; atypical antipsychotics may cause hyperglycemia)

• pramipexole
Vraylar (cariprazine)

+

pramipexole

1 interaction

Monitor/Modify Tx

cariprazine + pramipexole

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• pramlintide
Vraylar (cariprazine)

+

pramlintide

1 interaction

Monitor/Modify Tx

cariprazine + pramlintide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• prazosin
Vraylar (cariprazine)

+

prazosin

1 interaction

Monitor/Modify Tx

cariprazine + prazosin

monitor BP, especially during prazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• pregabalin
Vraylar (cariprazine)

+

pregabalin

1 interaction

Monitor/Modify Tx

cariprazine + pregabalin

monitor respiratory rate: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cariprazine may decr. seizure threshold)

• procarbazine
Vraylar (cariprazine)

+

procarbazine

1 interaction

Monitor/Modify Tx

cariprazine + procarbazine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• prochlorperazine
Vraylar (cariprazine)

+

prochlorperazine

1 interaction

Monitor/Modify Tx

cariprazine + prochlorperazine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), extrapyramidal symptoms, hyperthermia (additive effects)

• propafenone
Vraylar (cariprazine)

+

propafenone

1 interaction

Monitor/Modify Tx

cariprazine + propafenone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• propofol
Vraylar (cariprazine)

+

propofol

1 interaction

Monitor/Modify Tx

cariprazine + propofol

monitor BP, respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• propranolol
Vraylar (cariprazine)

+

propranolol

1 interaction

Monitor/Modify Tx

cariprazine + propranolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• protriptyline
Vraylar (cariprazine)

+

protriptyline

1 interaction

Monitor/Modify Tx

cariprazine + protriptyline

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• quazepam
Vraylar (cariprazine)

+

quazepam

1 interaction

Monitor/Modify Tx

cariprazine + quazepam

monitor respiratory rate, BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• quetiapine
Vraylar (cariprazine)

+

quetiapine

1 interaction

Monitor/Modify Tx

cariprazine + quetiapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• quinapril
Vraylar (cariprazine)

+

quinapril

1 interaction

Monitor/Modify Tx

cariprazine + quinapril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• ramipril
Vraylar (cariprazine)

+

ramipril

1 interaction

Monitor/Modify Tx

cariprazine + ramipril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• rasagiline
Vraylar (cariprazine)

+

rasagiline

1 interaction

Monitor/Modify Tx

cariprazine + rasagiline

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• remifentanil
Vraylar (cariprazine)

+

remifentanil

1 interaction

Monitor/Modify Tx

cariprazine + remifentanil

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• remimazolam
Vraylar (cariprazine)

+

remimazolam

1 interaction

Monitor/Modify Tx

cariprazine + remimazolam

monitor BP, respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of hypotension (including orthostasis, syncope), profound CNS and respiratory depression, psychomotor impairment (additive effects)

• repaglinide
Vraylar (cariprazine)

+

repaglinide

1 interaction

Monitor/Modify Tx

cariprazine + repaglinide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• riociguat
Vraylar (cariprazine)

+

riociguat

1 interaction

Monitor/Modify Tx

cariprazine + riociguat

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• risperidone
Vraylar (cariprazine)

+

risperidone

1 interaction

Monitor/Modify Tx

cariprazine + risperidone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, extrapyramidal symptoms, hypotension, including orthostasis, syncope (additive effects, duplicate therapy)

• ropinirole
Vraylar (cariprazine)

+

ropinirole

1 interaction

Monitor/Modify Tx

cariprazine + ropinirole

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• ropivacaine
Vraylar (cariprazine)

+

ropivacaine

1 interaction

Monitor/Modify Tx

cariprazine + ropivacaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• rosiglitazone
Vraylar (cariprazine)

+

rosiglitazone

1 interaction

Monitor/Modify Tx

cariprazine + rosiglitazone

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• rotigotine transdermal
Vraylar (cariprazine)

+

rotigotine transdermal

1 interaction

Monitor/Modify Tx

cariprazine + rotigotine transdermal

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• sacubitril
Vraylar (cariprazine)

+

sacubitril

1 interaction

Monitor/Modify Tx

cariprazine + sacubitril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• safinamide
Vraylar (cariprazine)

+

safinamide

1 interaction

Monitor/Modify Tx

cariprazine + safinamide

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• saxagliptin
Vraylar (cariprazine)

+

saxagliptin

1 interaction

Monitor/Modify Tx

cariprazine + saxagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• selegiline
Vraylar (cariprazine)

+

selegiline

1 interaction

Monitor/Modify Tx

cariprazine + selegiline

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• selegiline transdermal
Vraylar (cariprazine)

+

selegiline transdermal

1 interaction

Monitor/Modify Tx

cariprazine + selegiline transdermal

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• semaglutide
Vraylar (cariprazine)

+

semaglutide

1 interaction

Monitor/Modify Tx

cariprazine + semaglutide

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• sevoflurane
Vraylar (cariprazine)

+

sevoflurane

1 interaction

Monitor/Modify Tx

cariprazine + sevoflurane

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• sildenafil
Vraylar (cariprazine)

+

sildenafil

1 interaction

Monitor/Modify Tx

cariprazine + sildenafil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• silodosin
Vraylar (cariprazine)

+

silodosin

1 interaction

Monitor/Modify Tx

cariprazine + silodosin

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• sitagliptin
Vraylar (cariprazine)

+

sitagliptin

1 interaction

Monitor/Modify Tx

cariprazine + sitagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• sodium ferric gluconate complex
Vraylar (cariprazine)

+

sodium ferric gluconate complex

1 interaction

Monitor/Modify Tx

cariprazine + sodium ferric gluconate complex

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• sotagliflozin
Vraylar (cariprazine)

+

sotagliflozin

1 interaction

Monitor/Modify Tx

cariprazine + sotagliflozin

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• sotalol
Vraylar (cariprazine)

+

sotalol

1 interaction

Monitor/Modify Tx

cariprazine + sotalol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• sparsentan
Vraylar (cariprazine)

+

sparsentan

1 interaction

Monitor/Modify Tx

cariprazine + sparsentan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• spironolactone
Vraylar (cariprazine)

+

spironolactone

1 interaction

Monitor/Modify Tx

cariprazine + spironolactone

monitor BP: combo may incr. cariprazine and active metabolite levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism possibly inhibited, additive effects)

• sufentanil
Vraylar (cariprazine)

+

sufentanil

1 interaction

Monitor/Modify Tx

cariprazine + sufentanil

monitor respiratory rate, BP; decr. sufentanil start dose, consider decr. cariprazine dose, use lowest effective doses: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• suvorexant
Vraylar (cariprazine)

+

suvorexant

1 interaction

Monitor/Modify Tx

cariprazine + suvorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tadalafil
Vraylar (cariprazine)

+

tadalafil

1 interaction

Monitor/Modify Tx

cariprazine + tadalafil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• tagraxofusp
Vraylar (cariprazine)

+

tagraxofusp

1 interaction

Monitor/Modify Tx

cariprazine + tagraxofusp

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• tamsulosin
Vraylar (cariprazine)

+

tamsulosin

1 interaction

Monitor/Modify Tx

cariprazine + tamsulosin

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• tapentadol
Vraylar (cariprazine)

+

tapentadol

1 interaction

Monitor/Modify Tx

cariprazine + tapentadol

monitor respiratory rate, BP; decrease dose of one or both drugs, use lowest effective doses and shortest duration of concomitant treatment: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• taurine
Vraylar (cariprazine)

+

taurine

1 interaction

Monitor/Modify Tx

cariprazine + taurine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• telmisartan
Vraylar (cariprazine)

+

telmisartan

1 interaction

Monitor/Modify Tx

cariprazine + telmisartan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• temazepam
Vraylar (cariprazine)

+

temazepam

1 interaction

Monitor/Modify Tx

cariprazine + temazepam

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• terazosin
Vraylar (cariprazine)

+

terazosin

1 interaction

Monitor/Modify Tx

cariprazine + terazosin

monitor BP, especially during terazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• thioridazine
Vraylar (cariprazine)

+

thioridazine

1 interaction

Monitor/Modify Tx

cariprazine + thioridazine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), hyperthermia (additive effects)

• thiothixene
Vraylar (cariprazine)

+

thiothixene

1 interaction

Monitor/Modify Tx

cariprazine + thiothixene

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• timolol
Vraylar (cariprazine)

+

timolol

1 interaction

Monitor/Modify Tx

cariprazine + timolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• timolol ophthalmic
Vraylar (cariprazine)

+

timolol ophthalmic

1 interaction

Monitor/Modify Tx

cariprazine + timolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• tirzepatide
Vraylar (cariprazine)

+

tirzepatide

1 interaction

Monitor/Modify Tx

cariprazine + tirzepatide

monitor glucose if type 2 diabetes mellitus use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• tizanidine
Vraylar (cariprazine)

+

tizanidine

1 interaction

Monitor/Modify Tx

cariprazine + tizanidine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• tolcapone
Vraylar (cariprazine)

+

tolcapone

1 interaction

Monitor/Modify Tx

cariprazine + tolcapone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• torsemide
Vraylar (cariprazine)

+

torsemide

1 interaction

Monitor/Modify Tx

cariprazine + torsemide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• tramadol
Vraylar (cariprazine)

+

tramadol

1 interaction

Monitor/Modify Tx

cariprazine + tramadol

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, seizures, severe hypotension, including orthostasis, syncope (additive effects)

• trandolapril
Vraylar (cariprazine)

+

trandolapril

1 interaction

Monitor/Modify Tx

cariprazine + trandolapril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• trazodone
Vraylar (cariprazine)

+

trazodone

1 interaction

Monitor/Modify Tx

cariprazine + trazodone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• treprostinil
Vraylar (cariprazine)

+

treprostinil

1 interaction

Monitor/Modify Tx

cariprazine + treprostinil

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• triamterene
Vraylar (cariprazine)

+

triamterene

1 interaction

Monitor/Modify Tx

cariprazine + triamterene

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• triazolam
Vraylar (cariprazine)

+

triazolam

1 interaction

Monitor/Modify Tx

cariprazine + triazolam

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• trifluoperazine
Vraylar (cariprazine)

+

trifluoperazine

1 interaction

Monitor/Modify Tx

cariprazine + trifluoperazine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), extrapyramidal symptoms, hyperthermia (additive effects)

• trimipramine
Vraylar (cariprazine)

+

trimipramine

1 interaction

Monitor/Modify Tx

cariprazine + trimipramine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• valsartan
Vraylar (cariprazine)

+

valsartan

1 interaction

Monitor/Modify Tx

cariprazine + valsartan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• vardenafil
Vraylar (cariprazine)

+

vardenafil

1 interaction

Monitor/Modify Tx

cariprazine + vardenafil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• vosoritide
Vraylar (cariprazine)

+

vosoritide

1 interaction

Monitor/Modify Tx

cariprazine + vosoritide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• yohimbe
Vraylar (cariprazine)

+

yohimbe

1 interaction

Monitor/Modify Tx

cariprazine + yohimbe

monitor BP, especially w/ high yohimbe doses: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• zaleplon
Vraylar (cariprazine)

+

zaleplon

1 interaction

Monitor/Modify Tx

cariprazine + zaleplon

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ziconotide
Vraylar (cariprazine)

+

ziconotide

1 interaction

Monitor/Modify Tx

cariprazine + ziconotide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zolpidem
Vraylar (cariprazine)

+

zolpidem

1 interaction

Monitor/Modify Tx

cariprazine + zolpidem

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)